How long should we treat patients with newly diagnosed myeloma with bisphosphonates or RANKL inhibitors for their myeloma bone disease given recent data?

The excellent context within the question by @Dr. First Last answers 99% of what I was going to say. This is the MAGNOLIA trial that prompted this question:

Lund et al., PMID 38622134

This was a randomized trial of 2 versus 4 years of zoledronic acid in myeloma. Of the 30 cases of bone lesions they f...